Sunday, March 31, 2019

11 New Movies Coming Out in April 2019

There are plenty of great new movies coming out in April 2019, 11 of which are being released all across the U.S.

New Movies Coming Out in AprilNew Movies Coming Out in April Source: Wikipedia

The upcoming month will be an exciting one for comic book fans as the last Avengers flick in the series will be rolled out at the end of April. There’s still a lot we don’t know about the movie, but it has the potential of becoming the most exciting flick premiere of the decade.

It will generally be a good month for superhero lovers as Shazam! will make its way to a theater near you in the early part of the month. We will also get the new Hellboy film, which promises to be grittier than the 2000s version of it as it will be rated R, starring Milla Jovovich.

Outside of the cinema, April will also herald the return of the hit HBO show Game of Thrones, which is another massively popular cultural phenomenon that is nearing the end of its run. While the last season of the show will kick off next month, May will mark the end of the series and nothing will ever be the same again.

However, we’re focusing on cinematic adventures today, so here are the 11 major flicks coming out this April:

Friday, April 5 Shazam: PG-13/Superhero Pet Sematary: R/Horror The Best of Enemies: PG-13/Biography Friday, April 12 After: Drama Little: PG-13/Comedy Hellboy: R/Action Missing Link: PG/Animation Wednesday, April 17 Breakthrough: PG/Drama Penguins: G/Documentary Friday: April 19 The Curse of La Llorona: R/Horror Friday, April 26 Avengers: Endgame: Action Compare Brokers

Tuesday, March 26, 2019

Apple is keeping partners in the dark on video service packaging, pricing

Apple is going to announce its new video streaming service plans at an event in Cupertino, Calif., on Monday, March 25.

Over the past few months, CNBC has reported many details on Apple's plans. But the big open question is the pricing, and whether there will be any discounted bundles that encompass multiple services. A steep discount on available streaming video services could give consumers an immediate reason to sign up for Apple's new service.

Here's what people familiar with the company's plans have told us:

Apple is housing a new video streaming service in its TV app. Within that app, Apple is going to allow device users to subscribe to currently available streaming services, similar to Amazon Channels. This will likely include over-the-top (OTT) services such as Starz, Showtime, CBS All Access, Viacom's Noggin, HBO, and other existing channels, many of which can already be found on Amazon Channels. It will not include Hulu or Netflix. Users will be able to watch video in one dedicated application without having to flip between a variety of other company's streaming apps.Apple is investing in original content, at least some of which will be available for free to Apple device users within the TV application. Macworld put together a list of Apple's shows here.Apple has pushed for a 30 percent cut on every customer that subscribes to an over-the-top video service through its streaming service, people have told CNBC. Currently, Apple takes a 15 percent cut on revenue from customers that sign up to HBO Now, Netflix, and other streaming apps through the App Store.

While Apple may bundle some of these services together at a discounted price, we don't yet have details of how the bundles and pricing will work.

And here's the kicker -- its partners don't seem to know either.

Apple has been so secretive about its bundling plans that many of the main participants in its "channels" product don't know how it plans to package the services and what it plans to charge, according to people familiar. This sentiment was echoed by JPMorgan media analyst Alexia Quadrani:

"While we met with several companies participating in Apple's upcoming video service, none seemed to have a clear sense of what will exactly be announced on Monday," Quadrani wrote in a note to clients. "There is some consensus however that the product will include free original content plus a number of channels that consumers can purchase or view in one app using a single sign-on."

Bundling at a discount could differentiate Apple from Amazon Channels, which has thus far only sold its OTT services a la carte.

But the fact that the streaming services don't know details about any discounts suggests that any subsidized pricing will come out of Apple's pockets, as opposed to its partners' bottom lines.

Apple is also spending about $1 billion on its own original content. While several people have told CNBC that at least some of the content will be free to Apple device users, it's still uncertain how the video will be available (if at all) to non-Apple device users.

WATCH: This trader expects Apple streaming platform to make streaming easier

show chapters This trader expects Apple streaming platform to make things easier This trader expects Apple streaming platform to make streaming easier    7 Hours Ago | 02:42

Thursday, March 21, 2019

DSW Inc. (DSW) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

DSW Inc. (NYSE:DSW) Q4 2018 Earnings Conference Call Marc. 19, 2019, 8:30 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Ryan Kirsh -- Head of Investor Relations

All right. Good morning and welcome. My name is Ryan Kirsh. I'm the Head of Investor Relations. And thank you for joining us today. Before we begin, I want to call out that today, there will be forward-looking statements in our presentation. For those of you in the room, you can see on both sides of the screen, this is our statement. Please take a quick moment to read it. You can also find our forward-looking statements in our SEC filings, and it will be available in this presentation online after today's meeting. In this presentation, we will also talk about adjusted financial statements, which is a non-GAAP item. Please note that in the appendix on today's presentation online, you will be able to find a GAAP to adjusted reconciliation.

Now, I would like to introduce our leaders that will be talking to you today. First, Roger Rawlins, our Chief Executive Officer, will be discussing our vision and strategy. Then you'll hear from Bill Jordan, President of the DSW Segment; Mary Turner, President of the Shoe Company; and Simon Nankervis, President of the Camuto Group. Finally, you'll hear from Jared Poff, our Chief Financial Officer, who will provide our financial outlook for the company through 2021. There will be a question and answer session at the end of today's presentations. And for those of you following along on the webcast, you will be able to submit questions.

With that, it is now my great honor to present our first speaker, Chief Executive Officer Mr. Roger Rawlins.

Roger Rawlins -- Chief Executive Officer

Thanks, Ryan. Good morning, everyone. Three years ago, when I moved into this role here at DSW, what we talked about was we were going to build an elite team. And I'm so proud today to get the opportunity to introduce you to all of my teammates.

And when you look at our results that we delivered in 2018, I think they demonstrate the quality of the team that we have built; the 6% comp we delivered in 2018; the fact that when you adjust for the closure of the town enterprise, that we grew our earnings by 17% the last year; the fact that we bought back two million shares; the fact that we increased our earnings expectations twice in 2018 and delivered up on that. But I think more importantly, it's the fact, while we were doing all of that and driving the business, do what we do, we were also going after Camuto. We were also acquiring Shoe Company. So I think it really demonstrated the quality of the team that we have.

So today, I'm going to introduce you to my teammates. The first one -- frankly, I wouldn't be in this role if it weren't for her. DSW wouldn't be here if it wasn't for her. Her name is Debbie Ferree. Debbie, if you did not know this, there is a Shoe Hall of Fame, and Debbie is in the Shoe Hall of Fame. So please give it up for my partner Debbie Ferree. Next, you're gonna get the opportunity to hear from Bill Jordan.

Bill's been with the business for 13 years. Bill is now leading the DSW brand. Prior to that, Bill had served in just about every role you could possibly have within our corporate offices at DSW. But more importantly, a year ago, Bill had the opportunity to go to Canada and really help us manage this business that was transitioning to be a part of DSW Inc., so really happy to have Bill leading now the DSW brand across North America.

Next, you're gonna get to hear from Mary Turner. Mary joined our business two years ago. Great merchant, great retail expert in Canada, which is so important to us, because that's not an expertise that we have. So, so excited to have Mary on the team. And Mary's gonna talk to you a little bit about what we're doing with Shoe Company.

Next, you're gonna have the opportunity to hear from Simon. Simon joined our business three years taken, has taken over the Camuto enterprise. And what Simon brings to the table is experience in both vertical retail, which he did at American Eagle, but also on the wholesale side as well. So, perfectly positioned to lead the Camuto business.

Next, you're gonna get to hear from Jared. I've known Jared for over 20 years. Great background. Worked in vertical retail through Abercrombie. Worked in big box retail, a company called Big Lots you guys probably all follow, and a large, large company called Cardinal Health. So Jared is our CFO.

We also have three individuals that are not with us today but are back in our home office in Columbus that are sharing this message with our team in Columbus. We have Michelle Love -- 32 years with Nordstrom and joined our business about two years ago. We have Drew Domecq. Drew's our CIO. Drew has been with our business now for a year. Great experience in the invasion space with Wendy's. And we have Tom Jessop, who's been with our business for five years. And Tom leads our supply chain as well as our HR functions.

So next, I want to take you back to 1978. Do you guys remember 1978 at all? Okay. I do vividly, because in 1978, I was a 12-year-old, and I was the twelfth man on a 12-man basketball team. Do you guys know what that means? Okay. That means at the end of the game, there's 20 seconds left in the game. Your team is ahead by 20 points, or you're behind by 20 points, and the coach looks to the end of the bench, and he grabs Rawlins by the shoulder and says, "It's time for you to go in the game." I did not have a lot of self-confidence when I was 12 years old. But something changed. This. You might laugh, but this is the shoe that changed my life when I was 12. Why? Because my parents went out and invested in this shoe. Now, if you guys don't remember, back in the day, this was a crazy expensive shoe, because this is what Larry Bird, this is what Magic Johnson, Pistol Pete Maravich -- these guys were all wearing this.

Now remember, I'm the twelfth man. I never got in a game. But when I put these shoes on, when I came out, I made every single layup. I made every jump shot. Every single cheerleader was looking at Roger. Every single thing that was going on was about these shoes for me. They gave me a level of self-confidence.

That's what we're talking about today. That's the kind of energy we're gonna bring through our brands, that you're gonna hear those stories from each of my teammates. It's why today, I'm wearing Mercante. If you guys go out today, this is exclusive at DSW. Please go make a purchase this afternoon. I think we have some gifts for you. But I wanted to share that story because you're gonna hear several of those again today from my teammates.

So let's talk a little bit about our history. And when you think about what's happened, this business was actually founded 50 years ago. 50 years ago, by Jerome Schottenstein. And it started with this, doing lease businesses. So we get questions a lot about, you know, what's it like working in other retailers? We've been doing it now for almost 50 years. Then in the '80s, how this thing involved was they got into open cell concept.

They started loyalty programs. They did special makeup, all of these things that allowed DSW to be positioned differently in the marketplace, which led to the 2000s, which in 2005, we went public and really sort of set the stage for where we could go. Also at that time, we started rolling out our digital experience. Now I'm real proud of the fact that from 2008 to 2013, I got to lead our digital business and really did sort of help our business up for growth.

Then, in 2014, this changed. Our CEO then, Mike McDonald, and our board said, you know what? Things are happening to us. We don't know exactly what they are, but we've got to figure this out. So we went and created an innovation team. And we went and collected data all over the place. We looked at every part of retail. We looked at the consumer experience, how things were evolving, and we said, you know what? We have to change. And so, we went to What's Next, which you see that sort of posted all over the place. And we told this team, go put together what's next for this enterprise.

And I'm real proud of the fact that that team built the strategy -- the mission, vision, and strategy -- that we've been following since 2014. In 2015, we built out our infrastructure. And when I say infrastructure, we built what everyone calls omnichannel. And you know what? We were recently recognized as the number one omnichannel retailer in all of retail. I will tell you, we don't call it omnichannel. It's called the customer. And I think that lens is something we have always been lucky enough to have. Then in 2016, we rolled out Kids. So we added a new category to what we were doing day in and day out.

Then in 2017, we started testing services. So we went after nail services first, and you're gonna hear from Bill today, because this thing is killing it. This thing has great growth potential. This is attracting people to our brand. They create an emotional connection, no different than that shoe experience I had when I was 12 years old. Pretty soon, you'll be able to have a drink as you're having your nail service, and you'll be able to shop our brand. And it creates this emotional connection, again. And in 2018 -- you'll hear a lot about what we did this year from Bill -- we relaunched our rewards program. And it's the first time we'd really done anything with that program in 10 years. We did a six comp this year. Roughly half of that, I think you could credit to what we did within this whole concept.

So again, those were all things we did that were defined in 2014 as the direction we wanted to head. Then we said, now that we have this incredible infrastructure, what's next? What are we gonna do next? So we said, we have to grow. We have to find ways to get into new markets. We have to find ways to create new products, differentiated products. So we acquired Shoe Company and acquired the Camuto Group.

So, what does that mean? That means we are a dramatically different business in 2019 than we were at the start of 2018. We now have our three owned companies -- Camuto, DSW, Shoe Company. We also have our two lease businesses, Stein Mart and Frugal Fannie. So ultimately, this is a dramatically different company. So why did we have to evolve? Why did this all change? You guys ask us this question a lot. There were three big factors, and I think these are really, really important to understand why we've determined what's next and where we're headed.

The first one is this: technology. I see just about everyone in here has a device up in front of them. If you go back years ago, that wasn't the case, right? Technology changed consumer behavior. They have access to information at their fingertips they never had before. They have the ability to have price transparency. So our model was being challenged because our everyday value model was being offset by people discounting in the online space, right?

So we had to think differently. And the one that we kept referencing was electronics. And we talked a lot about this with our board. We are not going to stand by and let that happen to our company, to our 16,000 associates that we're so passionate about. We are not going to stand on the sideline and be HH Greg-ed, or Radio Shack-ed, or Circuit City-ed. We're going to be Best Buy of our space. That's the approach we took when we were looking at how we were going to evolve our business, which led to this.

As we looked at this next data point -- I've shared this, I think, with some of you. From 2011 to 2017, there were five companies -- I'd say five segments -- that really, really grew market share. And when I say really grew, they picked up 20 percentage points. Not 20 basis points -- 20 percentage points of market share, OK? The first one, a brand we all know and love: a company called DSW. We went from 3.1 to 3.3% market share from 2011 to 2017.

How did we do that? We did the old school way. Let's open stores. We incurred about a billion dollars -- I shouldn't say incurred. We invested about a billion dollars of our shareholders' cash opening those stores, and we grew market share, which was great. The challenge is these other elements. Number two. Who else grew? Athletics space, because guess what? You can't see everybody feet. More people are wearing sneakers than they were back in 2011. It's just the facts. So I think that segment had a sort of leg up on everyone else.

Next, Nordstrom. How? By the inline business, Nordstrom, they've done a nice job, but also the launching of Nordstrom Rack, which now we get to service through our Camuto enterprise. But this is the one everybody talks about and focuses on, and it's called Amazon, right? They're the big bad player that everyone should dislike in the industry. Why? Because from 2011 to 2017, they picked up almost six percentage points of market share. All of you guys talk about this. You're always asking us, what is it that you're gonna do to differentiate yourself from Amazon in those kind of things? The reality is, we want to partner with them, and we're figuring that out as a larger enterprise.

But this is the data point that you need to understand changed our mind on where we have to go. It's this: our vendor partners. We invested a billion dollars building our brand and their brands. Meanwhile, while we're building their brands, which we needed to do, technology has allowed the consumer to go around DSW and allowed that brand to go direct to consumer. They pick up 12 full percentage points.

Remember, these are the people that we are representing in our box. Again, an example of how we used data to say, we cannot let that happen. We are not going to sit on the sideline. We are going to think differently. We are going to find what's next, which also, as all of that was going on, you had this happening. You had brands that are being gobbled up, because guess what? If you can't do that direct to consumer thing, you'd better find someone that can help you, or else you're not gonna be relevant.

And so, that's what's happened. Caleres, Steve Madden, Marc Fisher, DSW. All of them have been buying brands, so there are fewer and fewer players, big players, that are out in that marketplace, which ultimately led us to say we've got to transform this enterprise. We have to drive value. We have to take control of our destiny. And what does that destiny look like? It looks like this, because now what we have is this world-class retailer called DSW -- the thing that's doing over $3 billion dollars in sales, that has over 500 warehouses with a kick-butt digital experience that involves their consumer, different experiences, different product. That's a core of what we do, driving a lot of cash.

We also have this new thing called Shoe Company, which gives us an edge in the last mile. And Mary's gonna talk about this. But envision how you can fill in market voids with a much smaller box that's much more targeted than something that is over 20,000 square feet providing all of the services we're providing at a DSW.

And then you marry that with this thing called Camuto Group, which is a world-class organization. Vince was a leader with Nine West of building brands, and Simon's gonna share that. So ultimately, when we do all of those things, when we bring all three of those to life, it is different than DSW. It is something dramatically different. It is something that's what next in this industry, and it is Designer Brands.

So, this is where we are going. This is what those three companies look like. This is a combination that no one else in our industry can match. We have the ability to build brands. We have the ability to bring product to life that differentiates experiences at DSW, at Shoe Company, and the ability to leverage this incredible infrastructure we have just spent 50 years investing in to do something dramatically different. So what does this mean day in and day out? It means our parent company is now Designer Brands. It means our ticker is gonna be DBI. It means how our associates connect with our brand is gonna be at a higher level than an individual brand that they work at. That is what Designer Brands looks like. But I want to share with you what Designer Brands looks like compared to what DSW Inc. used to look like.

DSW was only attached to about 20% of the total footwear market. That market was really restricted to just people that play in the space that we play in day in and day out, selling shoes and the retail concepts. With Designer Brands, we now have access to 80% of the footwear market. It's not just about us running stores. It's us playing in the wholesale space. It's playing in the direct to consumer space. I want you to think about these five things, OK? They are, first, Shoe Company gives us access to the Canadian market and gives us the ability to fill in around DSWs. That's number one.

Number two, our DSW digital expertise is going to be applied to Shoe Company and to Camuto. I mentioned on that vendor front how those vendors had gone after it in a big way to grab 12 percentage points. You're gonna hear from Simon, one of those brands that just does not know how to do that, has not had that expertise, is the Camuto organization. Digital penetrates less than 1% of their sales. Guys, think about that. 1% of their sales. We know how to do digital. That's what we can bring to the table.

Number three, we can expand this wholesale business that Camuto has been operating in a major way across our DSW, our Shoe Company platforms. Love to see more Jessica Simpson, look to see more Lucky, love to see other brands that ultimately, we can acquire as part of the Camuto Group.

Number four, we will build our private brands. We have a history of building brands. Bill will share in his presentation, as we were making those investments in stores, in our digital experience, we were growing brand sales faster than they were growing them themselves. That's an important fact I want you guys to think about as we talk about that. And then finally, what we want to do is take all of these things we've learned -- we know footwear.

We know footwear better than anyone else in our industry. We want to go share that with our other retail partners. We want to sit with Alex Dillard and share what we're doing with our rewards program to drive his footwear sales, just like we're doing with Stein Mart. And I'll go meet with Hunt on Thursday morning down in Jacksonville to share with them what it is we're doing and how that can impact their business. We want Nordstrom to sell more shoes. We just want them to sell our shoes.

So that's the direction we're headed as Designer Brands. It's dramatically different and has access to 8% of the market. And before. I talked about over a six-year period of time, we grew our market share 20 basis points, 3.1. to 3.3. In the last nine months, we've gone from 3.3% of the footwear in peoples' closets to over 5%. That's the way Designer Brands is going to be thinking.

Next, we had no brands that were produced in-house. Frankly, we've struggled to have success from this. Carol Lee from our board has always been challenging us over the last 13 years that we've been public, why can't you grow private brand? Why can't you grow private brand? Because we could never find the right partnership. And we tried a lot of players. We dated a lot of people in our industry. And we said, you know what? The only folks that really know how to do this, because they've doing it for years with Alex Dillard and Macy's, is the Camuto Group.

And so now, what we have is the capability to design, source, and market our own brands to develop differentiated product. And I want to share these data points. And I think we've talked about this in some -- I know in a couple luncheons we had. But think about this. At the beginning of 2008, the DSW brand had 800 labels that they dealt with day in and day out. That means we were putting 800 of these labels in front of the consumer.

The top 25 were really brands, right? Those 25, think of Nike, it's Skechers, it's Steve Madden -- it's those kind of folks. They accounted for 40% of our sales. Those are brands, because when someone's going online and they're looking on their device, the first thing they're looking for is that brand name. And you have to have them to present to the consumer that you know what are the appropriate brands. So you've got to have that in your mix.

Next, 75 -- I would call them item brands, meaning they have a key item that if you don't have it, the customer thinks you don't know what you're doing. Hunter Boot, as an example. Whatever that item might be, you've got to have it. That's 30% of our total sales. So 70% is really embedded in these top 100 sort of brands. The next 20% is 700 labels. Why are they even relevant to the consumer? Because we decided to put them on our selling floor, to put them on our website, to make them available to our 30 million rewards members we have across North America. That is where there's opportunity to grow our private brand from today about 10% to be closer to 25 or 30% over the next three years. That's the vision that we have.

Next, this one is probably my favorite -- limited visibility to cost. So let's talk a little bit about how we've historically cost goods. Remember, when we started, our heritage was closeout buying. In closeout buying, you don't have a lot of negotiating power, right? And the way we priced goods, we have something we want to retail for $50.00. We say we need a 60% IMU. So what do we do? We write a check for $20 bucks, and we say to that vendor, hey, we're not coming back to you for any more money.

We don't need any -- we don't come back for markdown money or any of those things. We know we're gonna take some markdowns. We'll margin out in the mid-40s. That is the way we costed goods. Guess what? That game has changed, because now, we have visibility and we understand how to manufacture footwear as Designer Brands. We have the ability to determine what costs we're going to pay.

I'm gonna give you the best example I can think of. We went to Nine West, and we looked at acquiring Nine West, and we got real close to pulling the trigger on that. We decided not to. As we did that assessment of Nine West, we were by far their best account. Why? Because we paid more for product than anyone else. We also didn't create a pain for them because we didn't come back and ask for markdown allowances and all the other things.

Then we went to Camuto. We did our due diligence at Camuto, and guess what? It was the same thing. The scorecard showed large department stores, their margins on their product is down here. Mid-tier department stores, the margin was here. The margin on DSW product is up here. Guess what? That game has to change. We will not accept that anymore. That is why Debbie is now the president of Designer Brands, because she's got those relationships over the past 22 years that we're gonna leverage so that we can have that conversation with the vendors and say, this is what we're going to pay for goods because we know this is what it costs. Major game-changer that you're gonna hear about today.

Next, we were only in the U.S. footwear market, right? Our DSW business was really isolated, focused on what we do here in the U.S. Where we're at now, as I mentioned earlier, the Shoe Company, we have the incredible opportunity to fill in market voids. We have the ability to grow DSW north of the border. Incredible opportunities to continue to expand as Designer Brands. We also were brand to brand retailer, so we were facing that challenge of the consumer going around us, the brands going direct to the consumer.

That's not where we're at now. We have a platform that will drive growth and consolidate this industry. That is the way we are thinking about it as Designer Brands. Ultimately what this gives us is the ability to control our own destiny. That has not been the case. We have been reliant upon others to deliver products on our behalf. We still will to a certain extent, but we now have the ability to go direct to consumer the same way everyone else has.

So ultimately, when you think of Designer Brands, this is what I want you to think of. We are brand builders delivering differentiated experiences powered by the scale of one of North America's largest footwear enterprises. That is who we are now. That is dramatically different than who we were as DSW. And you can see these -- we're gonna talk about these later, about how all of these come together, connecting all of these enterprises. So how do we win? It's doing this. Do what we do.

You're going to hear today, there isn't any secret thing we have to do. It's go and execute the way that we always have. It's Simon taking the Camuto Group with Alex and the team we have at Camuto and delivering the same thing they have done for Dillard's and they have done for Macy's -- just go do it for DSW. And guess what? They have the capacity to do that. If you're at DSW, keep continuing the seven consecutive quarters of positive comp you have generated, the momentum you have, and keep that ball rolling, and let's go grab share.

And if you're at Shoe Company, continue to execute the way that you have and leverage all the capabilities you now have at your fingertips by being connected to Designer Brands. When we do that, we will have differentiated products, we will have differentiated experiences, and we will grow market share. I mentioned the comps. Seven consecutive quarters, we're gonna keep that up. New categories -- Kids, Beauty, other things that we can bring to life. And ultimately, it's new markets, which will include us continuing to expand in Canada and finding ways to grow this enterprise.

So next, before -- or I'm sorry, as I finish up here, this is what all of you probably came today to hear. So what are we doing? What's the end result of all of these things? When you add it all up and you hear what each one of my teammates are gonna be delivering, it is getting to that number -- $2.75, although Jared tells me I have to give you the range -- between $2.65 and $2.75. It's about a 17% compounded annual growth rate of earnings, is what we're targeting between now and the end of 2021. When we did this acquisition and you challenged us as to what does this mean to the shareholder, this is what it means, because we will have a differentiated brand, we will have differentiated experiences -- we'll have a growing company, both bottom line as well as top line.

So next, I want to bring up my partner running the DSW brand, Bill Jordan. But before Bill comes up, we have a brief video to show you -- what the future of DSW brand looks like.

Bill Jordan -- President, DSW Designer Shoe Warehouse

Good morning. DSW is a world-class retailer with a strong track record and a loyal customer base. As part of the unique Designer Brands model that Roger just shared, we are uniquely positioned to drive growth and profitability by just continuing to do what we already know how to do. I want to start by sharing a story. I love shoes. And what you have to know about me is I've been in the footwear business since the day I was born. And the reason I say that is that my father was in the footwear business from the time he was 13 years old until the time he retired at age 65. He worked as a store manager and a district manager, and was on the front lines of product and customer.

So when I graduated from law school -- yes, I'm a lawyer. Insert your lawyer joke here. When I graduated from law school, what do you think my dad bought me as a graduation gift? A new pair of shoes. And not just any pair of shoes, but a pair of black leather wingtips. They were gorgeous. They were probably the most expensive shoes my dad had ever bought in his life, and he gave them to me because he thought that that's what a lawyer should wear. And you know what? I wasn't a very good lawyer when I started practicing law, but that first day when I walked into that firm, I felt like a lawyer. I had confidence. I knew I belonged because of what I was wearing on my feet. That's the power of self-expression, and that's what shoes can do for people.

So who is DSW? We are a destination for brand name and designer footwear and accessories. We offer value, convenience, and differentiated experiences to our customers. We have over 500 warehouses -- we call our stores warehouses -- across the U.S. and Canada. We have a world-class digital site. And we have a sticky 26 million members in an award-winning loyalty program. We have a consistent track record of growth. We are a growth company. We've grown sales each of the last 27 years. That's every year that DSW has been in existence.

Last year, we posted a +6% comp. As Roger mentioned, we've made investments over the last five or six years to make sure that we've got momentum to propel us for positive comps going forward. Those investments include investments in our omnichannel capabilities, where we've been awarded Best Omnichannel Retailer in America. Inventory management and supply chain capabilities that allow us to get the right shoes to the right place at the right time. Marketing programs that allow us to engage millions of customers and influence their buying decisions. And our loyalty program, which is one of the most successful loyalty programs across industries.

We have a very strong and engaged customer base. As we've already mentioned, we've got 26 million members in the U.S. engaged in our loyalty program. And looking at these charts, you can see that our transaction growth correlates to the growth of our loyalty program. We have grown our customer base substantially over the last decade, with over 90% of our sales coming from members in our loyalty program. What does this mean for us? It means that we've got data on our customers, and we know how to use that data to drive sales, create better experiences for our customers, and be more efficient with our marketing. This gives us a strong base for continued growth.

Within the DSW segment, we believe we can drive 13% operating income growth CAGR over the next three years. 13% CAGR. All's we need to do -- we don't need to do it on anything more than a low single-digit comp. We have three pillars that are gonna -- strategies that are gonna drive that growth: differentiated product, differentiated experience, and operational excellence. And I'm gonna walk through each of those three for you this morning.

First, I want to take you through how we think about product. As Roger touched on, we are brand builders. We've helped major brands grow their businesses through DSW, like Caleres, Skechers, and Steve Madden, to name just a few. This slide shows the combined sales of Caleres and Steve Madden over a 15-year period of time. From public data, wholesale sales of Caleres and Steve Madden have grown at an 8% CAGR over those years. Well, at DSW, they've grown at 12%. These brands grew their business 50% faster through DSW than through their other locations. Combined, we did $375 million in sales with these two brands last year. We are a key driver of growth for other brands and will continue to be so in the future.

We've also been able to create and grow our own brands, like Kelly & Katie and Mix No. 6. In that same 15-year period, we've grown our exclusive brands -- and exclusive brands are brands that are only available at DSW -- from $0 to almost $300 million. In fact, our Kelly & Katie brand is the number two brand that we sell in our entire assortment, and our customers love it.

Why are exclusive brands important? Three reasons. One, it allows us to offer differentiated product to the customer. Two, it allows us to offer great value to our customers. And three, it margins out substantially higher than the balance of our assortment. I'm really excited about the relationship we have formed with the Camuto Group because of this. They are industry leaders in creating private brands for other retailers, and they're gonna help propel us on our journey to grow our private brand substantially.

As Roger said earlier, we're taking control of our own destiny and disrupting the footwear business through this Designer Brands model. One of our key strategies is to grow the amount of product that we sell that we also produce, over $700 million by the end of 2021. This means selling more product produced and made by the Camuto Group. These sales will be a combination of our exclusive brands, like Kelly & Katie and Mix No. 6, and Camuto-produced wholesale brands like Lucky and Jessica Simpson. Together, we call this Camuto-produced brands.

And why is it important that we sell Camuto-produced brands? Well, number one, it gives us the chance to sell unique and differentiated product to our customers. Number two? Camuto-based products will have higher margin than the balance of the assortment at DSW, and Designer Brands gets to capture both the retail and wholesale margins associated with those sales. And third, as we grow the Camuto brands, we'll naturally need to reduce the choices and the balance of our assortment. That means we will use that limited shelf space that is available to go to our vendors and let our vendors compete for space on our floor, which means we can push on costing and quality to make sure we've got the best in business.

This slide shows the breadth of our offering -- our own exclusive brands and other brands that we now make through the Camuto Group. As Roger said today, our top 25 brands make up about 40% of our sales. Those are brands we must have on the floor. The next 75 brands make up 30% of our sales, and those are important, and we've got to have them as well. But the next 700 brands, which represent 20% of our sales, are really not brands. They're labels, and they're only there because we've chosen to put them on the floor. We can replace those labels that don't have brand equity with brands that we are producing through the Camuto Group that have growing brand equity and margin out better the DSW and Designer Brands enterprise.

Next, I want to turn to Kids. We recently introduced Kids to our warehouses, and the customer is responding. We are the fastest-growing retailer in Kids shoes, and we have a lot of runway in front of us. The Kids footwear market is about $6.5 billion, or roughly 10% of the total footwear market. In a short period of time, we've grown our Kids sales to almost 4% of our sales and are targeting 10% of our sales by 2021. That's an incremental $185 million in footwear sales over the next three years.

But the reason we entered Kids was not to sell kids shoes. It was to sell more adult footwear, and it's working. We are attracting a new customer. We are driving additional traffic to our warehouses. Customers that buy kids products are spending $75.00 more per year than non-kid buyers. And 31% of the time, when a kid's shoe is purchased, an adult shoe is purchased. This strategy is working, and we've got to step on the accelerator and bring it to our customers even faster. We're gonna win at Kids, and it's gonna help propel our Adult comps along the way.

Now, I want to talk about seasonal product. Seasonal product is what we call our best ad strategy, meaning we want to be known for standing for this product. This is where we differentiate ourselves from other footwear retailers. And about 30% of our sales over the course of the year are in seasonal product. That gets as high as 40% during peak sandal and boot seasons. The customer response to our seasonal product is overwhelming. Last year, we grew that product by 10%, and it represented a large percentage of our incremental +6% comp growth. We're gonna put more receipts into boots and sandals, and believe we have a real opportunity to increase our sales in these key categories by having higher in-stocks in boots and sandals all year long.

Our second strategy is to build differentiated experiences. We've got to have a connection with our customers. And we have a history of being at the forefront of retail, and Roger talked about. But our experience always starts with our loyalty program. We originally launched our loyalty program in the early 1990s, well before other retailers even though about having a loyalty program. As I said, we have over 26 million active and engaged members, and over 90% of our sales come through our loyalty program. This program allows us to have a consistent and customizable way to engage with our loyalty customers.

In 2018, we relaunched this program and changed the name to VIP, and it's really working. We're adding new customers at a faster rate. We are increasing the percentage of sales coming through the program. Members are spending more per transaction, and we're retaining members at a faster rate -- higher rate than we ever have before. That's awesome. That's why Shopify recently named our VIP program the number one innovative customer loyalty retail program. But loyalty is more than just offering a discount on a future purchase, which we do, to the tune of $5.00 per every $100.00 spent.

Our program engages customers to establish an emotional connection and gives unique benefits and experiences, like gifts with purchase, for members only; or ways to earn points without making a purchase. As part of our VIP relaunch in 2018, we asked our members what benefits they wanted. Their response? The ability to donate shoes. So we partnered with Soles4Souls, and our customers in the past year have donated almost one million pairs of shoes. And we're giving customers loyalty points for donating shoes. It's a win-win all the way around, and we're gonna continue to innovate in our loyalty program.

But we're not done yet. In May, we will launch VIP phase three, which includes personalized benefits where you have the opportunity to pick what benefits are important to you and that you want to have. We're gonna offer one free next day shipping to all members, because we know speed is important sometimes. You need that shoe. We're gonna add mobile wallet and the ability to enroll in the program via SMS.

And by yearend, we're gonna launch phase four, which will create a DSW.com customer community; offer enhanced rewards for purchasing our exclusive brands, which ties back to our strategy on growing exclusive brands; create My Brands, which will identify customers' favorite brands based on past shopping experiences; and offer rewards for social media interactions. We're gonna continue to enhance this program because We know how much it means to our customers and how much it means to our bottom line.

We are innovators at DSW, and we are a disruptor in the footwear space. We have been testing services, as Roger said, within our warehouse, including nail bars, orthotics, repair services, and even testing subscription models. The customer is responding. We are seeing strong attachment rates and increased traffic into our warehouses by shoppers that frequently make use of these services. We recently announced that we're expanding our nail bar test to five additional locations this year, and we're very excited about that opportunity.

Along with services, we've created a redesigned store layout and fixture package that allows us to offer more choices to the customer, which is now in 10 of our stores. Innovation is the core of who we are and why we will continue to win in the future.

Personalization is so important, and personalization always starts with data. We've been able to gather a tremendous amount of data about our assortment and our customers because of our loyalty program in place. This data allows us to focus our assortments on customer preferences and drive customer engagement. First, we're using customer buying patterns to inform what shoes we put in what warehouses, which means we know what she's demanding and where she's demanding it, so we are evolving our assortments to have what she wants when she walks into our warehouse.

Second, we are using data to inform how we market to customers. We are targeting promotions to customers based upon their prior shopping patterns. This will allow us to offer customers the right promotion to drive purchases and eliminate less rich offers to customers who don't need them. We're also able to drive traffic through more targeted messages by using content in our messaging that is relevant to the customer. If we know the customer like to buy athletic shoes, then we're gonna serve messages that target athletic. If we know that she likes to buy Kelly & Katie, we're gonna send messages that send Kelly & Katie.

Our third strategy is around operational excellence, and this starts with inventory management. If we can get the right shoe in the right place at the right time, we will win. Easy said, hard to do. The number one reason a customer does not buy when she is in our store? We don't have her size. Guess what? Size matters. So what are we doing about this? We're increasing our key items by 20% this year. Key items are items that we buy in depth and have flow behind. Because of this depth, we have better in-stocks by size, which drives sales and conversion. It also creates better margins for us. How? Well, when we buy larger quantities, we get better pricing on shoes upfront. And second, when we stand for an item, our market down rate is substantially less.

An increase in key items also lets us edit the balance of the assortments, which means we're gonna decrease the number of non-key items sitting on our floor. What's the result of that? Higher in-stocks by size, a better customer shopping experience, and more sales and margin for DSW.

We're also focused on fulfillment optimization. Our digital penetration continues to grow and grow, and we've got huge momentum in the digital space. Where we fulfill orders from can drive sales and margin. As I've said, we've got the ability to use our inventory no matter where in our system it is -- any warehouse, any fulfillment center, any distribution center. So we've created an order routing algorithm that allows us to pick where a shoe is shipped from for a digital order. We look at a lot of factors when we do it, but the most important factor is to target a place that's most likely to take a markdown. Because if we can avoid a markdown, it'll help our margin substantially, our bottom line substantially. We're gonna continue to optimize this order routing algorithm because we know digital will continue to be a huge part of our business.

Operational excellence also extends directly into our warehouses. We've rolled out a new service model for our associates that focuses on operational excellence and engagement with our customers. When I talk about operational excellence, I mean running a neat, clean store, making sure associates are properly scheduled for when customers are there in the store, fast checkout lanes, flawless visual execution, and fulfillment accuracy. Engagement is about greeting the customer, enrolling new members into our VIP program, and executing our new service model. Our goal is to be operationally excellent and engage with our customer to drive conversion in our warehouses.

We also have to have strong execution as it relates to our digital site. We're gonna continue to invest here, and we call this continuous digital optimization. We've structured our team so that we're adding new features on a continual basis. What used to take weeks and months, we can now do in days. We've added headcount to support a continuous digital optimization, and we've rolled out new payment, AB testing, and personalization in the last six months. All these efforts are driving stronger digital conversion online, and we're excited about those results.

Finally, real estate -- this is a competitive advantage for us. First, our portfolio is strong and balanced. We have less than five stores that are not four-wall profitable, and about approximately 20% of our leases are up for renewal every year. That means we have huge flexibility, and if we need to change our footprint, we can do it quickly. Second, our warehouses have four benefits that we like to talk about. The first? It's a traditional store. You walk in, you buy a pair of shoes, you walk out. Second, it's a billboard for our brand. When we open a store in a new geography, our digital sales in that geography increase greatly. When we close a store, those sales go away. Warehouses drive digital.

Third, it's a return center for online demand. This is a big deal. Having the ability for a customer to return a product right to a warehouse is a key differentiator from some of our competitors who don't have that and you've got to send it back through the mail. And we know that 28% of the time, if she makes a return into our warehouse, she makes a purchase. Huge advantage.

Finally, fulfillment center for our digital orders. We've said that we are within 20 minutes of 70% of the population, and as speed to consumer becomes more relevant, we are close to the customer. Finally, as it relates to real estate, we've got the ability to open up another 100+ locations across the U.S. and Canada that can further drive top line growth.

So how are we gonna win at DSW? We've made a lot of key investments over the last few years, and we've honed our operating disciplines. We are one of the best performing retailers in the U.S., and we're gonna continue to be so. Our focus is on driving three key strategies to get to that 13% operating income growth CAGR: differentiated product, differentiated experience, and operational excellence. We are excited about being a part of this new Designer Brands model and the leverage and power it bring us to further disrupt the footwear market.

And now, I'd like to introduce my partner, Mary Turner, the President of The Shoe Company.

Mary Turner -- President, The Shoe Company

Good morning. I'm here to tell you about Designer Brands' business in Canada and also to share a little bit more about my banner, The Shoe Company. The Shoe Company is the backbone of Designer Brands' Canadian business. And today, I'm going to explain how its format positions it as a powerful last-mile solution and also as the perfect complement to the DSW segment business.

But I'll tell you my shoe story first. It all started when I was eight years old with a pair of white go-go boots. It was love at first sight. But more than that, I knew in that moment that fashion was absolutely my passion, and that was the business I wanted to be in when I grew up. So fast-forward to this year, when once again, white booties are a key fashion trend. Every time I look at my Rebecca Minkoffs or put them on, I think, how lucky am I that not only was I able to follow my passion, but this is the business that I'm in now that I've grown up?

But that's enough about me, because I'd much rather talk to you about what's going on with our business in Canada. We've been selling shoes here for 65 years. As you may know, the footwear market in Canada is about $7.6 billion and grew at 2% last year. Designer Brands in Canada is the third largest player in the market, and even more importantly, had the second highest growth rate last year. I'm very proud to tell you that we're number one share in Women's and number three share in Kids. More than 3.5 million Canadians belong to our loyalty program, which is about 10% of our overall population. And we have 27 DSW warehouses and 112 Shoe Companies -- 113 Shoe Companies -- sorry, we just opened one -- across Canada.

Now let's take a look at The Shoe Company, which is my other passion. If you ask about the difference between the DSW segment and The Shoe Company model, I think the videos tell it all. The Shoe Company is a small, friendly, family based retail chain. Quite frankly, we're a small scrappy team, but we love our Shoe Company business. We love that we make it easy for our customer with a carefully edited assortment in a simple, shoppable box, and most importantly, conveniently close to her home.

As I said, we are a family footwear solution, and 21% of our business is Kids. Overall, what our customer is looking for from us is athletic, comfort, seasonal, and everything she needs for her family. But in smaller markets, we're often the only game in town, so we make sure that we have an edited assortment that meets all of her needs.

We just completed a significant research project with Maru/Matchbox, both with customers, and more importantly, with non-customers. As part of our strategy to maximize the Shoe Company opportunity, this gave us some excellent actionable insights. So who is our customer? She's likely married, she usually has kids at home, and she's almost always a working home.

But here is the really interesting thing. As busy as she is, she loves to shop for shoes. More than half of our surveyed customers describe themselves as shoefies and have bought at least five pairs of shoes for themselves in the last 12 months, in addition to the purchases they'd made for their family. And here's what she says about us. Our great Kids assortment is a key differentiator for her, and we're definitely her seasonal destination, whether for sandals or for boots. But most importantly for us, she rates us above our competitive set on almost every criteria.

The two key takeaways that we had from the Maru survey are to get a larger share of our shoefies' wallet by ensuring we have exactly what she wants every time, and the critical important of driving top funnel awareness, as we actually do a very good job of converting the customer for consideration to purchase once we get them either into our store or onto our website.

This is to help you understand the very significant difference between the two formats. When you think about the success of the DSW Warehouse, it's in a 20,000-square-foot box in markets of 400,000 people or more. But here's the beautiful thing: The Shoe Company is successful and highly profitable in 4,000 square feet in markets as small as 50,000 or even less.

It reminds me of the high school experiment that we all did, which taught us that there's always room for the grains of sand, even when the jar looks like it's already full of rocks. The Shoe Company is just like that sand. Our small boxes in smaller markets close to where our customer lives provide a very broad network of storefront marketing, of efficient fulfillment, and ease of pickup and return for our customer. That's exactly what makes us a powerful last-mile solution.

And to further leverage that last-mile network with the launch of the new digital platform that I'm going to speak more about shortly, we'll expose the much broader DSW assortment on The Shoe Company website as well to ensure that we're maximizing not only her assortment options, but our inventory productivity. And we'll build the widest possible reach for Designer Brands' digital business in Canada that way.

So, what are our strategic pillars? It's around differentiated experiences, both between the two banners in Canada, as well as against our competition; it's about leveraging the scale of designer brands for the Canadian business; and it's about our growth engines, both digital and bricks and mortar. And all of these things will help us drive a 19% operating income CAGR over the next three years.

You heard from Bill that loyalty has been a key driver in the DSW segment success story. Up until now, in Canada, both The Shoe Company and DSW have shared one common banner agnostic rewards program. More clearly defining and supporting the two separate banner propositions on all touch points is a key objective as we go forward. So in support of that, as part of our commitment to delivering an authentic DSW experience in Canada, we'll be launching the hugely successful DSW VIP program in Canada in Q2 of this year. We can then leverage the very rich information from our Maru survey to tailor a dedicated loyalty program that creates an emotional connection with our Shoe Company customer, and that will launch in fall of 2019. Oh, sorry. Phase one and phase two.

This is really big news. Moving from a 1.5% spend to a 2.1% spend gives us a 14% increase in our marketing dollars. This increase spend is critically needed to drive the engagement and frequency with our existing customer, but even more importantly, to build a new customer acquisition. As I called out earlier, this was a key action point coming out of the Shoe Company survey, which clearly identified that segments that we should target with this increased spend. And again, in keeping with our commitment to deliver on a consistent and authentic DSW experience, as of this spring, we're mirroring the DSW U.S. marketing campaigns in Canada for that banner.

Leveraging scale is a significant win for the Canadian business. Our acquisitions by Designer Brands is a game-changer for us in Canada. I liken it to suddenly having a big brother and being able to play with all of his toys. We'll have access to a free trade zone this September, which will allow the businesses on both sides of the border to best use shared inventories. This will be a particularly big win for the private brand business, and it will facilitate the significant growth that both Bill and I have planned in partnership with Simon and the Camuto Group. Going from 150 locations to being part of a thousand points of distribution clearly has a significant opportunity with vendor negotiation, not just in terms of pricing, but also in terms of access to exclusive product and special makeups. And even things like associate training programs and best practices are greatly enhanced by being part of a larger entity.

But what's the biggest leverage win? It's about digital. Our digital replatform would absolutely not have been possible without the access to the award-winning U.S. ATG platform and the access to the IT team and all of their incredible best practices that Bill just spoke to you about. The Canadian footwear business penetrates at about 19% to total for digital. And I'm here to tell you that in the past, we at Designer Brands in Canada have lagged significantly behind that number and significant behind DSW segment's penetration in the U.S.

So, this is a really big deal for us. Our move to the ATG platform in April will address not only our functionality, but much more importantly, it will enhance our consumer experience on both banners' websites and will allow us to more than double our e-commerce revenue by 2021. And although this growth sounds very high, it's actually completely consistent with the results the DSW segment has already shown and delivered in the past.

We have room to grow both DSW and The Shoe Company. And not very many retailers have the appetite or the ability to make that statement. Quebec represents 25% of the Canadian population, and we're currently not in that market at all, so definitely an opportunity. We'll also continue the expansion in smaller markets for The Shoe Company right across Canada as we continue to build the reach of our last-mile network.

So, in summary, here's how we're going to win. We'll connect with our consumers through new banner-specific loyalty programs and significantly increase marketing investment. We'll leverage the scale of Designer Brands through shared inventories, vendor negotiations, and common platforms. And we'll drive growth through increased digital penetration and organic expansion in Canada. And we will deliver a 19% operating income CAGR over the next three years.

Thank you. And I'd now like to introduce Simon Nankervis, President of the Camuto Group.

Simon Nankervis -- President, Camuto Group

Thank you, Mary. Bill and Mary have already spoken to you about the unique components of their business models and how Camuto Group and Camuto-produced products are going to play into those models. I'd like to take a little bit of time this morning and explain to you what is Camuto Group and the world-class digital design and sourcing platform that we developed.

In November of last year, Camuto Group became part of DSW, which is now Designer Brands. And as part of that, we inherited design and sourcing and branded services. We have three major brands -- our namesake brand, Vince Camuto; and our licensed brands of Lucky and Jessica Simpson. And we believe that with the addition of Camuto Group, we are positioned to drive the future of Designer Brands. We're going to accelerate our growth into the private branded business. We're grow our existing branded business through our existing retail partners. And lastly, we're gonna expand our direct-to-consumer capabilities, which to this day have been very limited.

Our mission is simple. There's a lot of words, but if you think about it, we do two things. We design great shoes and brands that customers want to buy. That's what we do. How do we that? How did we get to this place? I want to take a couple of minutes just to walk you through the history of Camuto Group so you can understand how we got to this place.

In 2001, Camuto Group was founded through a relationship with Dillard's and Vince Camuto. At that point in time, Alex Dillard granted Vince the permission to build his exclusive brands. 18 years ago, this company was founded on the development of private brands. In 2002, we landed our first license agreement with Max Azria for the development of BCBG. And over the next five years, that brand grew into a significant footwear brand in North America. In 2005, Vince, as a visionary and an entrepreneur, recognizes the value of celebrity. When you think about it, 2005.

Today, we talk about a number of brands and number of celebrities, but that was at a time when celebrity was just starting. And they signed the master license to Jessica Simpson, and we still have the footwear license today. And that brand still represents north of $150 million of retail sales for our group.

In 2006, Camuto Group partners with Tory Burch to develop probably one of the largest and strongest North American footwear brands today. And the relationship has just ended. In 2009, at the request of his retail partners and after a number of people saying, "Come on, Vince, why don't you have your own brand? You do this for everyone else. You can it for yourself," they then launched their namesake brand, Vince Camuto, and they entered the license for Lucky brand. In 2010, they begin to license the brand Vince Camuto into a number of our categories -- men's apparel, fragrance, women's apparel -- and that licensing continues today. We also launched vincecamuto.com nine years ago.

In 2013, the company continues its expansion by launching Louise et Cie. And then in 2015, two big events happened. One, the company divests itself of the master license to Jessica Simpson, to sequential brands, and the Simpson family, but retains the rights to the footwear. But more importantly, in 2015, the founder and entrepreneurial leader of the company passes away. Most companies at that point look to their executive team and say, now you have to stand up, because without that visionary and without the patriarch of the family leading the company, you can only go one of two ways.

This team stood up, and in 2016, they had their best year ever. They continued to expand their portfolio and acquired a number of other brands, including the acquisitions of Sole Society, and they produced the most numbers of pairs of shoes the company has ever produced, 33 million pairs. 19 million pairs of private branded footwear, 14 million pairs of branded footwear.

In 2017, the company [audio cuts out] moving into a new state-of-the-art distribution center which was only just completed now. And then in 2018, the company goes through a sale process with a number of significant footwear companies participating in that acquisition process. And what's important about that process is this was not a process where it was a company who won because they paid more money than another company. The company that won the right to continue with Vince's legacy was the company that they chose, and that company was Designer Brands.

Who we are. So if you think about our history and contemplate everything that we've done, we have three very clear revenue streams. We have private brand, where we design and source product for retailers and for vertical brands. We have our branded business, where we own brans or we license brands. And then lastly, we have our direct-to-consumer business through vincecamuto.com and solesociety.com.

We have a common set of key competencies that run throughout all [audio cuts out] business. Those competencies have been built over our 18-year history. It is a muscle that has been honed. It is a group of talented individuals that have been assembled, and it is a global scale. If you think about it, the vision that we had for Designer Brands, there was one piece of that puzzle missing. And Camuto Group was the missing piece.

By bringing Camuto Group into the family, what we did was we de-risked the design and sourcing operations. Roger laid that vision out for you earlier. And all we're asking for Camuto Group to do is what we've done for 18 years -- make great shoes that people want to buy. It's product that we make for vertical retailers. It's product that we sell into wholesale. It's a product that we sell to the consumer. It's what we've done for 18 years, and we're just being asked to continue to keep doing it.

What is essential to the success of Camuto Group and our history of building and designing brands? It's our fundamental ability to understand what today's customer wants. And it's not just the ultimate customer; it's what our retail partners want. We spend a lot of time in meetings with our retail partners talking about what is their consumer looking for?

What does our assortment need to look like? How does our assortment fit their needs? It is a company that is known for exceptional quality. We walk into meetings and people say to us, "Hey, I've got a little bit of an issue with this shoe. Can you talk to me about it?" And we look at the shoe and go, "We understand where you're coming from." We go, "But you're asking us to stick to a higher standard than you expect other people." And they go, "Yeah, because you're Camuto. We expect it from you."

We give great value to our retailers, and we give great value to our customers. If you buy a shoe from us, you know you can rely on it. And we have industry-leading design and sourcing services. We are a company that was founded on it. Think about our DNA. Go back to the beginning. 18 years of doing this business for other people. So all we're gonna do is what we do best: keep doing that. Designing and sourcing great product and marketing great brands that customers want to buy.

Over the past 18 years, we have built an extensive and diverse global infrastructure around design, sourcing, development, production, distribution, and wholesale. Think about it. 50+ factories in 13 countries through six global design offices. Contemplate what we have done. We have managed to de-risk what DSW would have had to have done itself. Designer Brands has inherited an ability to access a global infrastructure without taking the risks. We don't have the loss of time. We don't have the potential of missteps. So how does this all come together? What are we gonna do with this amazing machine that we've now brought into the family?

We at Camuto Group are going to do three things. We're going to accelerate private brand through our existing partnerships with a core focus on accelerating our move into DSW private brand. We're gonna grow our branded business, so continue to partner with the retail partners we've got today and figure out how to grow that business. And lastly, we're gonna innovate through speed to market.

Now let me take you through each of those. As the leader in private brand and as a business that we've been doing for 18 years, we partner with most of the major retailers, and we partner with a number of vertical brands. In providing these services, we reach a billion dollars of retail sales and produced last year 12 million pairs. If you

Wednesday, March 20, 2019

5 Dividend Aristocrats Where Analysts See Capital Gains

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1136269506&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1136269506/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Getty

To become a &q;Dividend Aristocrat,&q; a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention &a;mdash; and furthermore, &q;tracking&q; funds that follow the Dividend Aristocrats Index &l;i&g;must&l;/i&g; own them. With all of this demand for shares, dividend growth stocks can sometimes become &q;fully priced,&q; where there isn&s;t much upside to analyst targets.

But we here at &l;a href=&q;https://www.etfchannel.com/&q; target=&q;_blank&q;&g;ETF Channel&l;/a&g; have looked through the underlying holdings of the &l;a name=&q;etfplace&q;&g;&l;/a&g;SPDR S&a;amp;P Dividend ETF (which tracks the S&a;amp;P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.

In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.

&a;nbsp;

&l;/p&g;&l;div class=&q;table-wrapper&q;&g;&l;table class=&q;hctblstyle&q; border=&q;0&q; cellspacing=&q;0&q; cellpadding=&q;0&q;&g;&l;tbody&g;&l;tr&g;&l;th align=&q;center&q;&g;Stock&l;/th&g; &l;th align=&q;right&q;&g;Recent Price&l;/th&g; &l;th align=&q;right&q;&g;Avg. Analyst 12-Mo. Target&l;/th&g; &l;th align=&q;right&q;&g;% Upside to Target&l;/th&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Becton, Dickinson&l;/td&g; &l;td align=&q;right&q;&g;$244.67&l;/td&g; &l;td align=&q;right&q;&g;$269.12&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;10.00%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Chevron&l;/td&g; &l;td align=&q;right&q;&g;$125.88&l;/td&g; &l;td align=&q;right&q;&g;$138.42&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;9.96%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Emerson Electric&l;/td&g; &l;td align=&q;right&q;&g;$68.79&l;/td&g; &l;td align=&q;right&q;&g;$75.45&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;9.69%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;VF Corp.&l;/td&g; &l;td align=&q;right&q;&g;$86.06&l;/td&g; &l;td align=&q;right&q;&g;$93.81&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;9.01%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Sysco&l;/td&g; &l;td align=&q;right&q;&g;$66.46&l;/td&g; &l;td align=&q;right&q;&g;$71.09&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;6.97%&l;/b&g;&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;

The average 12-month analyst targets are only targets for the &l;i&g;share price&l;/i&g; however, and each of these stocks are expected to pay dividends during that holding period &a;mdash; so the expected &l;i&g;total return&l;/i&g; if these stocks reach their analyst targets is actually the share price upside seen by the analysts &l;i&g;plus&l;/i&g; the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:

&l;div class=&q;table-wrapper&q;&g;&l;table class=&q;hctblstyle&q; border=&q;0&q; cellspacing=&q;0&q; cellpadding=&q;0&q;&g;&l;tbody&g;&l;tr&g;&l;th align=&q;center&q;&g;Stock&l;/th&g; &l;th align=&q;right&q;&g;Dividend Yield&l;/th&g; &l;th align=&q;right&q;&g;% Upside to Analyst Target&l;/th&g; &l;th align=&q;right&q;&g;Implied &l;i&g;Total&l;/i&g; Return Potential&l;/th&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Becton, Dickinson&l;/td&g; &l;td align=&q;right&q;&g;1.26%&l;/td&g; &l;td align=&q;right&q;&g;10.00%&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;11.26%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Chevron&l;/td&g; &l;td align=&q;right&q;&g;3.78%&l;/td&g; &l;td align=&q;right&q;&g;9.96%&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;13.74%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Emerson Electric&l;/td&g; &l;td align=&q;right&q;&g;2.85%&l;/td&g; &l;td align=&q;right&q;&g;9.69%&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;12.54%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;VF Corp.&l;/td&g; &l;td align=&q;right&q;&g;2.37%&l;/td&g; &l;td align=&q;right&q;&g;9.01%&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;11.38%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Sysco&l;/td&g; &l;td align=&q;right&q;&g;2.35%&l;/td&g; &l;td align=&q;right&q;&g;6.97%&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;9.32%&l;/b&g;&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;

Another consideration with dividend growth stocks is &l;i&g;just how much the dividend is growing&l;/i&g;. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the &l;i&g;prior&l;/i&g; trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.

&l;div class=&q;table-wrapper&q;&g;&l;table class=&q;hctblstyle&q; border=&q;0&q; cellspacing=&q;0&q; cellpadding=&q;0&q;&g;&l;tbody&g;&l;tr&g;&l;th align=&q;center&q;&g;Stock&l;/th&g; &l;th align=&q;right&q;&g;Prior TTM Dividend&l;/th&g; &l;th align=&q;right&q;&g;TTM Dividend&l;/th&g; &l;th align=&q;right&q;&g;% Growth&l;/th&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Becton, Dickinson&l;/td&g; &l;td align=&q;right&q;&g;$2.96&l;/td&g; &l;td align=&q;right&q;&g;$3.04&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;2.70%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Chevron&l;/td&g; &l;td align=&q;right&q;&g;$4.36&l;/td&g; &l;td align=&q;right&q;&g;$4.55&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;4.36%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Emerson Electric&l;/td&g; &l;td align=&q;right&q;&g;$1.93&l;/td&g; &l;td align=&q;right&q;&g;$1.95&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;1.04%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;VF Corp.&l;/td&g; &l;td align=&q;right&q;&g;$1.76&l;/td&g; &l;td align=&q;right&q;&g;$1.94&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;10.23%&l;/b&g;&l;/td&g; &l;/tr&g;&l;tr&g;&l;td align=&q;center&q;&g;Sysco&l;/td&g; &l;td align=&q;right&q;&g;$1.35&l;/td&g; &l;td align=&q;right&q;&g;$1.47&l;/td&g; &l;td align=&q;right&q;&g;&l;b&g;8.89%&l;/b&g;&l;/td&g; &l;/tr&g;&l;/tbody&g;&l;/table&g;&l;/div&g;&l;hr&g;

These five stocks are part of our full &l;a href=&q;https://www.dividendchannel.com/slideshows/dividend-aristocrats-list/&q; target=&q;_blank&q;&g;Dividend Aristocrats List&l;/a&g;. &l;a href=&q;https://www.dividendchannel.com/slideshows/dividend-growth-stocks/&q; target=&q;_blank&q;&g;Click here to find out the Dividend Growth Stocks: 25 Aristocrats &a;raquo;&l;/a&g;

Tuesday, March 12, 2019

Corbus Pharmaceuticals Holdings Inc (CRBP) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

Image source: The Motley Fool.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)Q4 2018 Earnings Conference CallMarch 12, 2019, 8:30 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Greetings, and welcome to the Corbus Pharmaceutical quarterly update conference call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press *0 on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ted Jenkins, Senior Director, Investor Relations and Corporate Communications. Thank you. You may begin.

Theodore Jenkins -- Senior Director of Investor Relations and Corporate Communications

Thank you, Donna. Good morning, everyone, and thank you for joining us for the Corbus Pharmaceuticals Fourth Quarter and 2018 Year End Update Conference Call and Webcast. At this time, I'd like to remind our listeners that remarks made during this call may state management's intentions, hopes, beliefs, expectations, or projections of the future. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the Safe Harbor provisions of the Federal Securities Laws. These forward-looking statements are based on Corbus' current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements.

Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Corbus files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on Securities and Exchange Commission's website. We encourage you to review these documents carefully. Joining me on the call today is Yuval Cohen, our Chief Executive Officer; Sean Moran, Chief Financial Officer; Craig Millian, our new Chief Commercial Officer; and Barbara White, our Chief Medical Officer.

It is now my pleasure to turn the call over to Yuval Cohen.

Yuval Cohen -- Chief Executive Officer, Director

Thank you, Ted. Good morning, and thank you, everyone, for joining us today. My name is Yuval Cohen. I'm the CEO of Corbus. 2018 was a transformational year for Corbus, and I want to take the opportunity today to review some of our key achievements, provide an update on our clinical programs, and walk you through some of the key themes for 2019. I will then provide a financial update before I will open the call for your questions.

In 2018, we made significant progress toward our mission of becoming the leading pharmaceutical company in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system, also known as the ECS, a master regulator of inflammation and fibrosis in the body. Our vision is important as it underpins everything we do, and it speaks to our long-term belief that the cannabinoid biology will become one of the hallmarks of medical advances in this coming decade. Furthermore, as a pioneer in the development of small molecules that binds the cannabinoid receptors, we believe that Corbus is uniquely positioned to become the leading source of endocannabinoid system targeting therapeutics.

Stepping back, cannabinoids is a term that is attracting a lot of interest, and I'd like to briefly remind you all of how Corbus fits into this landscape. Endocannabinoids are the body's own endogenous cannabinoid signaling molecules that play a role in keeping our body healthy. Phytocannabinoids are chemicals found in the cannabis plant, such as THC and CBD. They are extracted from the plants and are approved as therapy for significant medical problems such as severe childhood epilepsy, nausea and vomiting in people undergoing chemotherapy, and the loss of appetite and weight loss in people stricken with cancer.

But importantly, our compounds are neither endocannabinoids or phytocannabinoids. Our compounds, by the endocannabinoid system receptors in the body, that they do not exist in nature. In other words, they are artificial, or synthetic, cannabinoids. There are several advantages to this strategy of rationally designing small molecules to target the endocannabinoid system, including our small molecule drug candidates can be designed for the treatment of specific diseases. Their chemical structure can be optimized to preferentially target the CB1 cannabinoid receptor or the CB2 cannabinoid receptor, and to partially or fully activate or inhibit these receptors.

Our compounds can be designed to specifically target the ECS in certain organs, such as the liver or the brain, or alternatively, avoid certain organs, such as the brain. Unlike plant derived cannabinoids, our synthetic ones benefit from composition of matter patent protection with all the market exclusivity benefits that accompany that. Lastly, this therapeutic approach of controlling activation or inhibition of endocannabinoid receptors has broad applicability to inflammatory and fibrotic disease.

Corbus now leads in the development of first-in-class drugs targeting the endocannabinoid system. We plan to be the first to market with novel therapeutics that target inflammation and fibrosis through the regulation of the ECS. Lenabasum, a CB2 agonist, is in pivotal testing for the treatment of rare autoimmune disease, such as systemic sclerosis and dermatomyositis, and in late-stage testing for the genetic inflammatory disease cystic fibrosis, as well as, in a first-in-patient lupus study.

We believe we have the most innovative and largest pipeline of early stage drug candidates that target receptors in the endocannabinoid system. These include CRB-4001, a CB1 inverse agonist, that is being developed for NASH, and a preclinical library of over 600 rationally designed compounds. We have the largest patent portfolio protecting our compounds, targeting the endocannabinoid system for inflammation and fibrosis. And we control the global commercial rights for our compounds

To summarize, with unique drug candidates from early all the way to late stage, and strong intellectual property with patent protection and global commercial rights, we believe we are well positioned to capitalize on the large market opportunity for endocannabinoid system targeting drugs designed to treat a range of inflammatory and fibrotic diseases.

Over the past several quarters, we have achieved a number of significant corporate milestones. We now have a robust pipeline with multiple shots on goal and expanded target indications. Corbus has the exclusive worldwide rights to develop, manufacture, and market drug candidates coming from a library of more than 600 preclinical compounds that bind to the endocannabinoid system. CRB-4001 and the rest of this library are a strong foundation for our growth.

We also executed our first licensing deal to ensure lenabasum can reach patients worldwide. We licensed the commercial rights to lenabasum in systemic sclerosis and dermatomyositis in Japan to Kaken Pharmaceuticals. Kaken is an excellent partner for Corbus as we look to enter the Japanese market, which represents a significant opportunity for lenabasum with approximately 28,000 systemic sclerosis patients and 9,000 dermatomyositis patients. Importantly, the agreement calls for a $27 million upfront payment, and we are also eligible to receive up to an additional $173 million in milestones and double-digit calls after that.

We view our Kaken deal as a model to pursue similar licensing deals for commercial rights to geographies that we cannot reach ourselves, while providing near-term and future non-diluted capital to the company. Of particular focus next are South Korea and China. On January 30th, we closed on a $40 million public offering of common stock. Our current cash reserve is adequate to support the company through data in our two clinical -- key clinical studies, the pivotal study in systemic sclerosis, and the Phase 2b study in cystic fibrosis.

Another important milestone is the continued expansion of our leadership team. Recently, Craig Millian joined Corbus leadership as Corbus' first ever Chief Commercial Officer. Craig will develop and drive U.S. global marketing and commercialization strategies with an initial focus on our lead drug candidate lenabasum. Craig brings 25 years of experience building therapeutic brands and leading commercial organizations in pharmaceutical companies. We are pleased to have Craig with us on the call today, and I'd like to hand it over to him for a brief introduction.

Craig Millian -- Chief Commercial Officer

Thanks, Yuval. Let me start by saying I am thrilled to join Corbus at such an exciting time for the company. As a bit of background, I joined Corbus from EMD Serono, where I most recently served as Senior Vice President and Head of U.S. Neurology and Immunology. Prior to that, I held a number of commercial leadership roles at Vertex, Pfizer, and Sanofi. What attracted me to Corbus was, first of all, Yuval and the other talented members of the team, all of whom share an inspiring vision and a commitment to excellence. I've only been on board for a short time, but I've already witnessed the truly collaborative team-oriented environment that's been cultivated here. And it's a true source of strength for the company.

I'm also very excited about the science underpinning Corbus' work. Synthetic cannabinoid development presents a significant opportunity. As Yuval noted, this has the potential to be a truly groundbreaking therapeutic area in the coming years, and Corbus is at the forefront of developing novel synthetic cannabinoid medicines. I'm energized and excited to be joining such a talented team and I look forward to help building the commercial strategy and infrastructure as lenabasum moves toward the completion of key registrational studies in 2020.

While I'm currently head down as I get fully up to speed in my new role, I do look forward to meeting many of you in the coming months. And with that, I'd like to turn the call back over to Yuval.

Yuval Cohen -- Chief Executive Officer, Director

Thank you, Craig. Craig's appointment is an important milestone for Corbus, and we're confident that Craig's experience and leadership will drive a successful launch for lenabasum, which we expect to be in 2021.

We'd like to now provide an update on our clinical pipeline, starting with lenabasum. With that, let me turn the call over to Barbara to provide an update on our clinical pipeline. Barbara.

Barbara White -- Chief Medical Officer

Thank you, Yuval. Lenabasum, a CB2 agonist, is our lead clinical asset. Lenabasum is currently being evaluated in Phase 3 studies for systemic sclerosis and dermatomyositis, and in Phase 2 studies for cystic fibrosis and lupus. Patient enrollment and dosing in our Phase 3 RESOLVE-1 study for systemic sclerosis remain on track and we anticipate the last patients by May. We are on track for study completion in the first half of 2020, and we anticipate NDA submission at the end of 2020.

We are optimistic that lenabasum has the potential to provide clinical benefit to patients with systemic sclerosis. Our optimism is based on the mechanism of action of the drug, benefit in animal models of the disease, consistent improvement in multiple efficacy outcomes in the double blind placebo controlled Phase 2 of lenabasum in systemic sclerosis, as well as its open label extension, and evidence of improvement of inflammation and fibrosis biomarkers in skin of study subjects.

We also remind you that lenabasum has orphan drug and fast track designations for treatment of systemic sclerosis with the FDA, and orphan drug designation for treatment of systemic sclerosis with EMA. Our Phase 3 DETERMINE study is a registrational study testing safety and efficacy of lenabasum as a treatment for dermatomyositis, our second potential rare autoimmune disease indication. Corbus has received input on study design from regulatory authorities in the U.S., Europe, and Japan. This study is enrolling subjects. It will be the largest interventional study to date in dermatomyositis. We will keep you informed as key milestones occur.

Our Phase 2 study of lenabasum evaluating effects on the rate of pulmonary exacerbation in patients with cystic fibrosis is also ongoing and on track for data in 2020. The study is enrolling patients 12 years of age and above at high risk for pulmonary exacerbation without regard to CFTR mutation, pulmonary pathogens, or background medications. The study is funded in part by a development award for up to $25 million from the Cystic Fibrosis Foundation that follows a $5 million award we received in 2015.

Lenabasum has orphan drug and fast track designations for treatment of cystic fibrosis with the FDA and orphan drug designation for treatment of cystic fibrosis with EMA. The NIH conducted lupus clinical study is progressing and we look forward to its completion.

With that, I'll turn it back to Yuval.

Yuval Cohen -- Chief Executive Officer, Director

Thank you, Barbara. Lenabasum presents a significant market opportunity for these three initial indications, with potentially up to $5 billion and 350,000 patients in the seven major markets. This includes approximately $1.4-2.2 billion in peak annual potential sales for systemic sclerosis, with 200,000 patients in the U.S., Europe, and Japan; approximately $1-2 billion in peak annual potential for dermatomyositis, with approximately 80,000 patients in the U.S., Europe, and Japan; approximately $700 million to $1 billion peak annual potential sales for cystic fibrosis, with approximately 75,000 patients in the U.S. and Europe.

Turning to CRB-4001, we continue to plan initiating a Phase 1 study of CRB-4001 in 2019, expected to be followed by an NIH, National Institute of Health, sponsored Phase 2 study in NASH. CRB-4001 is a second generation inverse agonist targeting peripheral organ fibrosis with strong preclinical data. In addition to lenabasum and CRB-4001, we expect to start one or two new clinical programs each year based in large part on the development and progression of drug candidates from our internal library, beginning in 2020. We are very excited about the potential for our robust pipeline and look forward to providing an update with the first candidate(s) we select later this year.

Now, let me briefly comment on our financial position. As we enter 2019, we have a strong balance sheet to help drive our operations through pivotal Phase 3 data for lenabasum. We ended 2018 with approximately $42 million in cash, but this figure does not include the $27 million Kaken upfront licensing payment, nor does it include the proceeds from our $40 million recent public offering. As a reminder, our partnership with Kaken alone will provide up to an additional $173 million upon achievements of certain regulatory, development, and sales milestones as well as double-digit royalties.

Before I turn the call over to question and answers, let me reiterate that 2018 was a truly transformational year for Corbus and we are proud of what we have accomplished. We closed two significant transactions that expanded our pipeline and advanced our vision to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system. We've taken the steps to prepare for the commercialization and eventual marketing strategy for lenabasum following the completion of key registrational studies next year, including hiring of our first ever chief commercial officer, and continue to anticipate significant annual market opportunity for lenabasum of approximately up to $5 billion.

Our registrational study of our lead compound lenabasum in systemic sclerosis is progressing well, with completion on track for the first half of 2020. Our Phase 2b study for lenabasum in cystic fibrosis is also expected to lead out in 2020. With such significant milestones supporting us, we are confident that 2019 will be a very important year as we continue the clinical development of lenabasum, initiate the clinical development of CRB-4001, and select the first drug candidates to send to clinical trials from our large compound library.

In conclusion, we are proud of our achievements to date, especially in light of the significant strides we've made as a company over a relatively short timeframe, from what was initially an entrepreneurial start-up over four years ago, Corbus has grown significantly. We have raised over $168 million in equity capital while successfully growing a high quality institutional investor base and expanding our research coverage by top tier investment banks. We believe that cannabinoid innovation is one of the most meaningful scientific advances under way, and we are excited about the opportunities available to Corbus as a leader in this space.

We are excited about -- for the future of the Corbus, and the many opportunities we have to create meaningful solutions for patients as well as drive value for our shareholders.

...

We will now be happy to take your questions. Operators, please go ahead.

Questions and Answers:

Operator

Thank you. At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press *1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press *2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the * keys. Once again, that is *1 to register questions at this time. Our first question is coming from Liisa Bayko of JMP Securities. Please proceed with your question.

Liisa Bayko -- JMP Securities LLC -- Analyst

Hi. Good morning. How are you?

Yuval Cohen -- Chief Executive Officer, Director

Morning, Liisa.

Liisa Bayko -- JMP Securities LLC -- Analyst

I wanted to welcome Craig to the team ask you what are your plans between now and commercialization? What are some of they key activities you'll be doing? And then, maybe you can comment a little -- you threw out some numbers for market size, which implies some idea about price ranges. Maybe you can ballpark that for us as well. Thank you.

Craig Millian -- Chief Commercial Officer

Yeah, sure. Hi, Liisa. Thank you for the welcome. I think I'll start by getting out and starting to meet with some of our KOLs and patient advocates, and really getting grounded in the science and the current treatment patterns in the disease. We'll continue to define the commercial opportunity and certainly build on our market research. I think we want to continue to -- Yuval gave a range of forecasts. I think we'll continue to refine that. I think it's a really good start. Obviously, we'll be building out some initial launch plans and starting to think about a range of options in terms of our go-to-market strategy for our different markets and our different indications.

We'll be thinking about our value proposition and thinking about the possibilities of our data and our label, and the implications for that. So, we'll want to start thinking about that from a payer perspective. And obviously, we'll start to identify some key capabilities and gaps in our staffing that we'll want to start to fill with some key hires. So, those are all some of the things I'll be focused on.

The numbers that Yuval quoted were from a fairly robust assessment -- commercial assessment that was done by Health Advances -- completely objective piece of analysis that they did, and was based on both published data as well as some primary research they conducted with KOLs and payers in the U.S. and in Europe. I don't want to get into the specifics of the pricing at this point. I would say, I think it was a fairly reasonable assumption that was built in in terms of both the pricing assumption as well as the penetration with the different indications to come up with that range.

But again, I thin it's a little premature at this point, so we'll continue to dig into that and refine our assumptions, as I mentioned, and continue to acquire data and market research to validate those. And we'll share those in due time.

Liisa Bayko -- JMP Securities LLC -- Analyst

Okay. Great. Thanks. And then, just one question maybe for Barbara. For your foray into NASH, can you maybe talk about your mechanism? Is it primarily surrounding the inflammatory component or do you see other contributions? Obviously, NASH is a complex disease with multiple different ways to target, either through fat, fibrosis, through inflammation. Where does your compound play?

Barbara White -- Chief Medical Officer

Liisa, thank you so much for that question. CRB-4001 is a CB1 inverse agonist. That means that inhibits CB1. And by doing that, we will have effects on multiple pathways that seem to be involved in the pathogenesis of NASH. First, we would anticipate having beneficial effects on metabolic pathways. It has been shown that inhibiting CB1 can help with insulin resistance, with glucose metabolism, energy metabolism. It helps with lipogenesis. So, it helps restore a number of the underlying metabolic abnormalities that many patients with NASH have.

Secondly, it's also been shown to have affects on both inflammation and fibrosis, which are the aspects of the disease pathogenesis that drive the initial aspects of liver damage and then the final cirrhosis that can lead to the need for liver transplant, or even hepatocellular carcinoma. So, targeting CB1 to inhibit it has the potential to effect those three very important pathways -- metabolic abnormalities, inflammation, and fibrosis. And we think that's a therapeutic edge.

Indeed, Johnson & Johnson also has put effort into targeting CB1, inhibiting CB1, in the treatment of NASH. They are doing it with a monoclonal antibody, which we think also is external valuation of the potential clinical benefit of this approach.

Liisa Bayko -- JMP Securities LLC -- Analyst

Thanks a lot, guys.

Operator

Thank you. Our next question is coming from Brian Abrahams of RBC Capital Markets. Please proceed with your questions.

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

Hey, guys. Thanks so much for taking my questions and congrats on all the progress.

Yuval Cohen -- Chief Executive Officer, Director

Good morning, Brian.

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

My first question is around the ongoing clinical studies. With the RESOLVE systemic sclerosis study nearing completion of enrollment, I was wondering if you could maybe speak a little bit, I guess, qualitatively about the types of patients who've entered that study and the work that you've done to ensure that it's a refined population, and you've eliminated the chance that patients with burned out disease are entering the study. And I guess, as a corollary to that, I know it's early days in the dermatomyositis Phase 3, but wondering if you could maybe talk a little bit about how the initial setup there is going, the types of patients, and the mix that you're getting enrolling in that study relative to expectations, and whether you have any sense as to what this initial enrollment trajectory might mean for potential timelines there. And then, I had a couple of follow-ups. Thanks.

Barbara White -- Chief Medical Officer

Certainly, Brian. Thanks. And if I forget part of that, just nudge me about it. So, first of all, regarding the SSc Phase 3 study, that study and all the studies were all blinded to treatment assignment. So, all I can say is what does the group in general look like. And it looks like what we expected, and will look like many other studies that have been done in patients with diffused cutaneous systemic sclerosis. So, both in terms of age, gender -- we've covered many geographies -- U.S., many European countries, Japan, South Korea, Australia. We expect to have a very representative group of patients so that clinical benefit can be determined again in a representative group of patients.

I would point out that we have made reasonable attempts to identify patients who could benefit from treatment. That's the way I'd like to couch our patient selection -- folks who could benefit from treatment. And we've selected patients with -- who have disease duration of no more than three years without any other requirement because, in general, they are thought to be able to have need for treatment, to be able to benefit, wither it is in skin, lung, joints -- whatever. There are multiple ways those patients can benefit, and we will capture.

Similarly, we allow patients who have disease ranging from three to six years if they have a certain level of skin involvement, so that again there's -- at least that component of the disease is measurable. Improvement would be measurable. So, we're very, very comfortable with the type of patients that we've enrolled. There's been nothing unexpected and we look forward to seeing the results and completing that enrollment very soon.

In terms of dermatomyositis study, again it's an important question. How do you know you have got patients who represent those who have the disease and who can benefit? First of all, the inclusion criteria that we selected allow us to include patients who represent the breadth of the disease -- those with classic dermatomyositis that is muscle involvement and some skin -- variable degrees of skin, but very definite muscle involvement, through folks who have very definite skin involvement and minimal, if any, clinically apparent muscle involvement. So, that whole range is included. The outcome that we have, the total improvement score, is adequate to measure clinical benefit in that range of patients.

We have selected patients who have to have certain degrees of disease activity, and that is based upon the types of involvement they have. First of all, the physician has to say they have active disease. So, they have to put it on a piece of paper that the patient's active, which is almost as good as anything, as well as they have to have a certain degree of muscle involvement, a certain degree of skin involvement, you have to have a certain degree of global abnormalities. So again, I'm quite confident we've got the right patients, the right outcome, and the right inclusion criteria.

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

That's very helpful, Barbara. Thanks. And then, we noticed that the structure of CB2 was recently published. Just wondering how that might further facilitate the interrogation and development of additional CB2, and CB1, targeted treatments within the compound library that you now have as you look to bring some of these compounds forward next year. I would love to hear about the types of compound profiles that you might be looking to pursue there.

Barbara White -- Chief Medical Officer

Well, thank you. I'm just so happy to have that question. First of all, about the crystal structures -- and I would say, actually, the silicone model of how our CRB-4001, our CB1 inverse agonist, actually binds to CB1, has been published already. And we will do similar in silicone models for our pipeline candidates as they move along because it will help inform us about a number of potential properties. This is just a part of the data that we are building as experts in this field, the types of interactions we want with particular regions, particular parts of the binding regions. So, we will do that for all of the compounds that we move forward into the clinic as part of our interrogation of their potential benefit.

It allows us to actually tweak molecules as well, as we develop our own set of internal compounds by determining just what we want to engage or not engage. So, very useful information for us, and we are using it currently, and we'll continue to use it in silicone modeling.

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

That's really helpful. Last question for me, maybe on the commercial front. Perhaps a question for Craig. You spoke about some of the initial marketing activities that you'd be pursing this year. How should we think about, as a commercial buildout and strategy takes shape and new hires come on board, the potential impact to the cadence of SG&A expenses, maybe over the course of this year as the year progresses and then in subsequent years. Thanks.

Sean Moran -- Chief Financial Officer

Hey, Brian. It's Sean Moran here. So, we put our guidance with the cash resources we have is over $100 million. So, we are funded through data into the fourth quarter of 2020. So, it covers all of those activities that Craig will be undertaking.

Craig Millian -- Chief Commercial Officer

I think for this year --

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

Thank you so much.

Craig Millian -- Chief Commercial Officer

Yeah, I think for this year, they'll be primarily strategic activities and fairly minimal amounts of hiring. Obviously, the cadence of hiring as we get data out next year, and as we approach filing our NDA -- then those things will pick up. But not so much this year.

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

Thanks so much.

Operator

Once again, that is *1 to register any questions at this time. Our next question is coming from George Zavoico of B. Riley FBR. Please go ahead with your questions.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Thanks. Good morning, everyone, and welcome, Craig, to Corbus Pharmaceuticals. Quick question about Kaken and its responsibilities in Japan and your responsibilities there, and when we might expect the first milestones, including whether you anticipate any clinical trials that might have to be done specifically in Japan. And how much -- I guess, the question basically is how much responsibility does Kaken actually have in Japan in overseeing both the development, the regulatory pricing, etc. there.

Yuval Cohen -- Chief Executive Officer, Director

Hey, George. It's Yuval. And --

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Hey, Yuval.

Yuval Cohen -- Chief Executive Officer, Director

-- and wonderful seeing you last week, by the way. Kaken is our partner in Japan. On a very simplistic basis, our responsibility is to wrap up the systemic sclerosis study in Japan -- remember, we have 10 Japanese clinical sites, as well as, obviously, undertake the upcoming dermatomyositis study Japanese sites. The study has already started elsewhere, but not in Japan. So, Kaken's responsibility -- regulatory responsibility. They will be our liaison and, in fact, represent us from now on at PMDA. And of course, commercial responsibility. That means negotiating the pricing with the Japanese authorities as well as going out there and actually marketing and selling the drug.

In terms of the milestones, they are, of course, confidential. But, George, you should think about them as fairly standard. They involve regulatory milestones -- you can probably guess what those are -- commercialization milestones, and sales milestones. Very, very standard for this type of deal.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

And does the set of milestones apply both to the systemic sclerosis and dermatomyositis?

Yuval Cohen -- Chief Executive Officer, Director

Correct. The deal in Japan is --

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Individually and parallel?

Yuval Cohen -- Chief Executive Officer, Director

The deal in Japan is for just Japan, which is interesting, and just for systemic sclerosis and dermatomyositis. Yes. The answer is yes.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Oh, OK. Thanks for that. With regards to NASH, you mentioned that it's NIH sponsored, the first trial. How do you expect to transition from NIH sponsorship -- or when, I suppose -- in the course of the clinical development, to transition from NIH sponsorship to Corbus sponsorship?

Barbara White -- Chief Medical Officer

So, I think that it is -- again, I view it as a very tight partnership with the NIH. We will do typical Phase 1 testing when we have the typical Phase 1 data available. We are working in collaboration with the NIH to develop the design of the next study, or studies, which will look at blood-brain barrier penetration and will also look at a number of biomarkers, and perhaps even some liver imaging, in patients with metabolic syndrome and/or NASH. So, those designs are not complete, but it will be done in very close discussions with the NIH. Thereafter, it's entirely up to Corbus what we decide to do. So, think of the NIH as extremely helpful in the interlude in determining of impact on biomarkers and blood-brain barrier penetration.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

But it'll be NIH money that'll run the first trial, or Corbus.

Barbara White -- Chief Medical Officer

We will run and pay for the Phase 1 SAD/MAD. They will run and look after and pay for internal project -- the NIH. It's been a long-term interest of Dr. George Kunos. They will do the study of the biomarkers in the patients -- Phase 2 patients -- with NASH metabolic syndrome.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

So, it's a shared funding, in other words. You both have defined responsibilities that you will be paying for then, right?

Yuval Cohen -- Chief Executive Officer, Director

So, for the Phase 1, George, it's on our dollar. And, of course, the nice thing about Phase 1 is that they're very affordable. And then, for the first in-patient Phase 1b/Phase 2a, the only obligation we have is to supply the drug to the NIH.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Okay. That's good. That's a good arrangement.

Yuval Cohen -- Chief Executive Officer, Director

Yes. Very happy with it.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Yuval, when you mention your market sizes, you talked about systemic sclerosis, for example, in very general terms. And yet, the trial is really diffuse cutaneous. So, can you break down a little bit what proportion of the total -- what you call systemic scleroderma eligible -- patient population in general and which ones are actually eligible for the trial and eligible, perhaps, once it's approved for that indication?

Barbara White -- Chief Medical Officer

I'm going to handle that. This is Barbara. The proportion of the subject --

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Thanks, Barbara.

Barbara White -- Chief Medical Officer

-- diffuse cutaneous systemic sclerosis varies from study to study. But I think 45% is a reasonable ballpark range. In terms of what the label will say -- don't forget. That's important. We don't have a label yet. You're absolutely correct that the study population's patients with diffuse cutaneous systemic sclerosis, I do not know if the label will say systemic sclerosis or diffuse cutaneous systemic sclerosis. So, I'm going to leave it at that.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

So, in other words, each one of these trials has defined, prespecified subgroups to take a look at that will define what the label eventually will say, based on, obviously, the results for each of the subgroups. Is that fair to say for both scleroderma and DM?

Barbara White -- Chief Medical Officer

I'm sorry. Would you mind just repeating that, George?

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Well, the question is whether you have prespecified subgroups within the broader systemic sclerosis and dermatomyositis populations. And depending on those subgroups, some might perform better than others, and that might inform what the label will say eventually.

Barbara White -- Chief Medical Officer

I'm going to say that there are always subgroup analysis in any --

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

 True. Okay, good.

Barbara White -- Chief Medical Officer

-- trial. And --

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Mm-hmm. True.

Barbara White -- Chief Medical Officer

-- that they're -- you should expect the same with ours. I am not going to speculate what the label will say at this time.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Well, yeah. Of course, that's going to depend very much on the --

Barbara White -- Chief Medical Officer

And the difference --

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

-- results, of course.

Barbara White -- Chief Medical Officer

And I did want to point out what is the difference -- folks that might not know -- what's the difference between diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis. It's really defined clinically by what parts of the body the skin -- the physician thinks the skin is thickened. In diffuse cutaneous systemic sclerosis, it's upper arms, upper legs, or trunk. They have to be involved, and in limited less so. So, for example, if the physician thinks that the skin thickening stops just below the elbows, that would be limited. If the physician thinks the skin thickening extends just above the elbow, that would be diffuse -- and the trunk.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Okay.

Craig Millian -- Chief Commercial Officer

One thing I'll just add in terms of the market assessment that Yuval referenced, we did take into consideration penetration rates based on disease severity, diffuse versus limited. So, we did actually -- even in this piece of research, look at different segments and assign penetrations accordingly. Again, we don't know ultimately what the label will be and what the data will be to output fairly reasonable assumptions, I think, for this point in time.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Okay. Thanks. And a final question regarding your -- the 600-plus compound library. And maybe this is part of the commercial strategy question for Craig. I mean, there's a lot of opportunities there, more than likely -- too much so, perhaps, for a company your size. Is there a licensing strategy that's going to be part of the commercial strategy?

Craig Millian -- Chief Commercial Officer

George, let me embrace that one with both arms. The answer is resoundingly yes. If the -- if you think about it, our vision really is to become the go-to company for these synthetic, rationally designed compounds that bind to endocannabinoid receptors. Some disease make perfect sense for us to go out and commercialize and market ourselves, particularly rare diseases. But there are many other inflammatory diseases, fibrotic diseases, where it makes perfect, perfect sense to actually partner with a big pharma.

What I'd like to emphasize to you, and all of our audiences, is our conviction that this coming decade will be a decade where most, perhaps even all, big pharma will embrace cannabinoid biology. We're already seeing that. And at that case, each big pharma has a choice. They can either develop their own cannabinoid, which will be expensive, lengthy, cumbersome. Or they could partner with the leading company that has, I believe, achieved a really unique position -- almost a dominating position -- around our understanding of the biology, the depths our pipeline, our medicinal chemistry capabilities, and also our patent strategy. I think the latter makes much more sense.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

And then, to that point, I presume that you're still growing the library.

Craig Millian -- Chief Commercial Officer

That is a very safe assumption.

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

Okay. Great. Thank you very much.

...

Operator

Thank you. This brings us to the end of today's question-and-answer session. Corbus Pharmaceuticals would like to thank you for your interest in today's conference. You may disconnect your lines at this time, and have a wonderful day.

Duration: 48 minutes

Call participants:

Theodore Jenkins -- Senior Director of Investor Relations and Corporate Communications

Yuval Cohen -- Chief Executive Officer, Director

Sean Moran -- Chief Financial Officer

Barbara White -- Chief Medical Officer

Craig Millian -- Chief Commercial Officer

Liisa Bayko -- JMP Securities LLC -- Analyst

Brian Abrahams -- RBC Capital Markets LLC -- Analyst

George B. Zavoico -- B. Riley FBR, Inc. -- Analyst

More CRBP analysis

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

10 stocks we like better than Corbus Pharmaceuticals HoldingsWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Corbus Pharmaceuticals Holdings wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 1, 2019